TRAW Traws Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1130598 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,159.3%
TTM net income YoY90.5%
TTM EPS YoY95.1%
Revenue 3-yr CAGR132.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-554.6%
Net margin-467.6%
FCF margin—
EBITDA margin-554.0%
Returns
ROE-1,059.6%
ROA-124.5%
ROIC (approx.)—
Asset turnover0.27x
Leverage & solvency
Liabilities / assets63.5%
Debt / equity0.00x
Current ratio1.22x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio57.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.79M | $226,000 | $226,000 | $226,000 | $226,000 |
| R&D expense | $12.14M | $12.85M | $11.43M | $11.41M | $7.30M |
| SG&A expense | $8.52M | $12.29M | $9.09M | $8.45M | $9.43M |
| Operating income | -$17.88M | -$142.37M | -$20.30M | -$19.63M | -$16.50M |
| Pretax income | $9.17M | -$166.53M | -$18.95M | -$18.96M | -$16.16M |
| Net income | $9.17M | -$166.52M | -$18.95M | -$18.96M | -$16.16M |
| EBITDA | -$17.81M | -$142.36M | -$20.28M | -$19.61M | -$16.48M |
| EPS (basic) | 0.83 | -35.21 | -22.57 | -0.91 | -0.96 |
| EPS (diluted) | 0.82 | -35.21 | -22.57 | -0.91 | -0.96 |
| Weighted avg. shares (diluted) | 8.38M | 1.55M | 839,554 | 20.91M | 16.83M |
| Balance sheet | |||||
| Cash & equivalents | $3.82M | $21.34M | $20.82M | $38.76M | $55.07M |
| Receivables | $3.79M | $1.76M | $18,000 | $29,000 | $28,000 |
| Current assets | $7.98M | $24.95M | $22.66M | $39.35M | $55.43M |
| PP&E, net | $7,000 | $10,000 | $22,000 | $24,000 | $38,000 |
| Intangibles | $2.53M | — | — | — | — |
| Total assets | $10.62M | $24.96M | $22.68M | $39.37M | $55.48M |
| Current liabilities | $11.15M | $11.53M | $9.22M | $8.05M | $6.12M |
| Total liabilities | $11.25M | $56.59M | $12.01M | $11.06M | $9.36M |
| Shareholders' equity | -$629,000 | -$31.63M | $10.67M | $28.31M | $46.12M |
| Shares outstanding | 9.07M | 3.65M | 840,251 | 20.93M | 20.90M |
| Cash flow statement | |||||
| Operating cash flow | -$18.18M | -$29.79M | -$17.93M | -$16.29M | -$19.49M |
| Capital expenditure | $2.58M | $3.65M | $14,000 | — | — |
| Free cash flow | -$20.77M | -$33.44M | -$17.95M | — | — |
| Investing cash flow | -$2.58M | -$3.65M | -$14,000 | — | — |
| Financing cash flow | $3.20M | $33.98M | — | — | $55.56M |
| Depreciation & amortization | $61,000 | $12,000 | $16,000 | $14,000 | $14,000 |
| Stock-based compensation | $728,000 | $1.39M | $1.30M | $1.17M | $576,000 |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.